United States securities and exchange commission logo





                          December 15, 2023

       Michael Davidson
       Chief Executive Officer
       NewAmsterdam Pharma Co N.V.
       Gooimeer 2-35
       1411 DC Naarden
       The Netherlands

                                                        Re: NewAmsterdam Pharma
Co N.V.
                                                            Registration
Statement on Form F-3
                                                            Filed December 7,
2023
                                                            File No. 333-275932

       Dear Michael Davidson:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Brianna M. Bloodgood